William Blair Has Positive Outlook of IPSC FY2024 Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC) – Equities research analysts at William Blair boosted their FY2024 earnings estimates for shares of Century Therapeutics in a report issued on Tuesday, November 5th. William Blair analyst S. Corwin now anticipates that the company will earn ($1.64) per share for the year, up from their previous estimate of ($1.88). The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.80) per share. William Blair also issued estimates for Century Therapeutics’ Q4 2024 earnings at ($0.44) EPS, Q1 2025 earnings at ($0.46) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS and FY2025 earnings at ($1.81) EPS.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.08. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The firm had revenue of $0.79 million during the quarter, compared to analysts’ expectations of $0.47 million. During the same quarter last year, the business posted ($0.55) earnings per share.

IPSC has been the subject of several other reports. HC Wainwright cut their target price on shares of Century Therapeutics from $9.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday. Chardan Capital reduced their target price on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Rodman & Renshaw started coverage on Century Therapeutics in a research note on Thursday, August 8th. They set a “buy” rating and a $6.00 price target for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $11.60.

Century Therapeutics Price Performance

Century Therapeutics stock opened at $1.44 on Friday. Century Therapeutics has a 1 year low of $1.14 and a 1 year high of $5.51. The firm’s 50 day moving average price is $1.51 and its 200-day moving average price is $2.22. The stock has a market cap of $122.44 million, a P/E ratio of -0.78 and a beta of 1.41.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its position in Century Therapeutics by 6.1% during the second quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock valued at $422,000 after purchasing an additional 9,500 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Century Therapeutics during the 1st quarter valued at $47,000. Vanguard Group Inc. lifted its position in Century Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 1,138,653 shares of the company’s stock worth $4,760,000 after buying an additional 14,000 shares during the last quarter. SG Americas Securities LLC purchased a new position in Century Therapeutics during the third quarter worth $27,000. Finally, Rhumbline Advisers increased its position in Century Therapeutics by 56.0% during the second quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock valued at $134,000 after acquiring an additional 18,828 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.